Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Patients with cancer-associated thrombosis (CAT) are at high risk of recurrent venous
thromboembolism (VTE) and major bleeding complications. Risks vary significantly between …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background The relation between cancer and arterial thromboembolism (ATE) remains
unclear. Objectives The purpose of this study was to evaluate ATE risk in cancer patients …

The treatment of venous thromboembolism (VTE) in patients with cancer is challenging
because these patients have increased risks of both recurrent VTE and major bleeding …

Background Patients with cancer‐associated venous thromboembolism (VTE) are
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …

Background Data on recurrence after the end of anticoagulation for a first event of cancer-
associated venous thromboembolism (VTE) are scarce. Objectives Our aim was to assess …

Gastrointestinal (GI) bleeding is the most frequent single site of oral anticoagulant (OAC)‐
associated major bleeding. Patients with major GI bleeding experience morbidity and a …

Cancer‐associated venous thromboembolism (VTE) is a leading cause of morbidity and
mortality in patients with cancer. Treatment of cancer‐associated VTE comes with a …

The burgeoning integration of 3D medical imaging into healthcare has led to a substantial
increase in the workload of medical professionals. To assist clinicians in their diagnostic …